Physician profile
Jonathan M Tarrash
NPI 1568434975
$1,143.02
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $201 · 2021: $362 · 2022: $63.17 · 2023: $52.79 · 2024: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $465.73 | 2019-2024 | Xtampza, Belbuca |
| Biodelivery Sciences International, INC. | $134.75 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2019 | |
| Stryker Corporation | $71.03 | 2020 | |
| Intuitive Surgical, INC. | $66.78 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $31.99 | 2022-2023 | Seglentis |
| Bioventus LLC | $30.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.66 | 2022 | |
| Ethicon US, LLC | $23.96 | 2019 | |
| Daiichi Sankyo INC. | $22.71 | 2019 | |
| Valinor Pharma, LLC | $22.37 | 2024 | Movantik |
| Zimmer Biomet Holdings, INC. | $21.28 | 2019 | |
| Redhill Biopharma INC. | $21.16 | 2021 | |
| Pfizer INC. | $17.54 | 2019 | |
| Indivior INC. | $16.30 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.52 | 2019 | |
| Si-Bone, INC. | $14.10 | 2019 | |
| Medtronic USA, INC. | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Tarrash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.